QCG
MAZE

Quadrant Capital Group’s Maze Therapeutics MAZE Stock Holding History

Quadrant Capital Group’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$120 – 2696
2026
Q1 		$120 Buy
+4
New +$177 ﹤0.01% 2689

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Quadrant Capital Group's MAZE Position: Q2 2026 in Review

Quadrant Capital Group sold out of Maze Therapeutics (MAZE) in Q2 2026, closing a stake of 4 shares — an estimated $120 sold.

Quadrant Capital Group first reported a position in MAZE in Q1 2026 and held it in 1 quarter. The position peaked at $120 in Q1 2026. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Quadrant Capital Group reported no remaining Maze Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 4 Maze Therapeutics shares in Q2 2026, an estimated $120.
  • Quadrant Capital Group first reported a position in Maze Therapeutics in Q1 2026 and held it in 1 quarter.
  • Quadrant Capital Group's Maze Therapeutics position peaked at $120 in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.